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Abstract
Background: The Centers for Disease Control and Prevention (CDC) convened a workgroup to
revise the tuberculosis (TB) case report in the United States of America (U.S.). The group
proposed substantial revisions. Study objectives were to systematically assess the validity and
completeness of reported TB case surveillance data in California and to inform TB case report
revision process.
Methods: A sample of 594 cases was retrospectively selected from the cohort of all TB cases
reported during 6/1/96-5/31/97 to the State TB Registry. Cases, stratified by treatment outcome,
were randomly sampled within each outcome category. Data for 53 variables were abstracted from
each case's public health medical record and compared to data recorded on the TB case report.
Using the medical record as the "gold standard," estimates were developed for 1) concordance,
sensitivity, and positive predictive value of reported data for categorical variables; 2) the absolute
mean difference between the two information source for date variables; and 3) the completeness
of data on the case report and in medical record.
Results: At least 90% of the values for 35 (79.5%) categorical variables submitted on the TB case
report form were identical to values in the medical record. Concordance between data on the case
report and medical record was lower for the remaining nine (20.5%) categorical variables: status of
abnormal chest x-ray (46.8%); directly observed therapy (48.6%); smear result for tissue or body
fluid other than sputum (49.2%); type(s) of tissue or body fluid for smears and cultures other than
sputum (76.4% and 73.9% respectively); provider type (73.4%); occupation (84.4%); sputum culture
conversion (85.4%); and sputum smear result (89.6%). Case report data were more complete than
data in the medical record; 2.9% versus 9.8% of data were missing/unknown, respectively.
Conclusion: For most variables examined on the TB case report, data validity was excellent,
indicating a robust surveillance system. However, lower data quality was noted for a small number
of variables primarily impacting treatment adherence, including assessment and planning; advocacy;
allocation and garnering of resources; and research. The study provides compelling evidence
supporting the CDC workgroup's proposed revisions to the TB case report.
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Background
Tuberculosis (TB) surveillance data are essential to evalu-
ate the effectiveness of TB control programs, identify defi-
ciencies, and design and assess interventions. Surveillance
data are also critical in advocacy efforts and in garnering
and allocating resources. For these reasons, the World
Health Organization's (WHO) enhanced DOTS initiative
[1-3] and the Centers for Disease Control and Prevention
(CDC) emphasize the importance of monitoring and
evaluating program performance [4,5]. In order to per-
form these important functions, it is essential that the
right variables are collected and reported in a timely man-
ner, and that these data are valid and complete. Inade-
quate data quality may impair our understanding of the
true epidemiology of TB, compromise core program func-
tions, and undermine our ability to meet program objec-
tives and goals. Although the availability of accurate and
complete TB surveillance data varies considerably by
region and by country, these data provide an essential tool
for local, national, and global efforts to control and elim-
inate TB.
Since 1985, all 50 states within the United States of Amer-
ica (U.S.) have collected and submitted data for each con-
firmed TB case to the CDC on the Report of Verified Case
of Tuberculosis (RVCT). In January 1993, in response to
the TB resurgence in the U.S., CDC increased the length of
the RVCT from 1 to 4 pages, the number of questions from
23 to 41, and the number of variables from 37 to 114
[6,7]. The RVCT collects the following categories of infor-
mation on confirmed TB cases: personal identifier, demo-
graphic, social/behavioral risk factor, clinical, treatment,
outcome, and case management. The CDC convened a
workgroup of local and state TB surveillance directors to
examine the need for revisions to the RVCT and accompa-
nying instructions. Over a two year period, the workgroup
developed a draft that proposed substantial revisions. At
this time, RVCT revisions are still in process. As the draft
undergoes review by stakeholders, further revisions are
anticipated, with implementation of the revised case
report form planned for 2008 (V. Robison, Chief of Sur-
veillance Team, Division of Tuberculosis Elimination,
CDC, personal communication; 6/8/06).
In California, a state which for many years has reported
over 20% of U.S. TB cases, medical providers report sus-
pected and confirmed TB cases to the 61 local health juris-
dictions in which the case resides. Local health
departments report confirmed cases, either electronically
or manually, to the California TB Registry in the state
health department. This reporting occurs: 1) at TB case
confirmation; 2) when the health department receives ini-
tial drug susceptibility test results (for culture positive
cases); and 3) when final treatment outcome information
is available, typically 6–18 months after treatment is initi-
ated. Local health departments may also submit updated
information to the State TB Registry subsequent to the ini-
tial case report submission. After the submission of
RVCTs, State Registry staff perform systematic quality con-
trol (QC) checks of data and collaborate with local TB reg-
istry staff to ensure valid and complete data.
To our knowledge, there are no published studies that
have comprehensively assessed the validity and complete-
ness of TB surveillance data in the U.S. or within Califor-
nia. Two U.S. researchers who examined the quality of TB
surveillance data for a small number of variables found
inaccuracies when comparing information obtained from
public health medical records and electronic case reports.
In one report, a state health department found substantial
differences in the values of ten variables at six local health
districts [8]. In another study of causes for delayed treat-
ment completion in three state cohorts, incorrect report-
ing in one state resulted in misclassification of therapy
completion status for 36% of its cases [9].
The primary objectives of this study were to systematically
assess the validity and completeness of RVCT data in Cal-
ifornia and to inform the RVCT revision process.
Methods
This evaluation of the validity and completeness of TB sur-
veillance data used data from two sources: 1) a case study
conducted by the California Department of Health Serv-
ices in 1999 on adverse outcomes during treatment of Cal-
ifornia TB patients; and 2) RVCTs submitted to the
California TB Registry for cases in this study population.
There were 594 cases in the study population, sampled
from a cohort of 2,627 eligible cases reported during 6/1/
96-5/31/97 to the California TB Registry. Cases in the
study population met the following criteria: alive at diag-
nosis; started TB therapy for culture positive TB disease;
resided in one of 18 California counties reporting ≥ 50
cases during the study period; did not move outside Cali-
fornia during TB treatment; had drug susceptibility testing
results available. A stratified random sample design was
used to select cases by reported treatment outcome. The
sample consisted of 17.7% of patients who completed
treatment, 93.2% of patients defaulting from treatment
(defined as patient lost, uncooperative, or refused treat-
ment), and 46.7% of patients who died during treatment
reported in the study period. RVCTs from all 18 participat-
ing local health jurisdictions were submitted electroni-
cally to the California TB Registry.
Study research staff performed an in-depth review of the
public health medical record at the local health depart-
ment for each case in the sample. Because the reviewed
records consisted of public health medical records only
and were used for public health research, institutionalBMC Public Health 2006, 6:217 http://www.biomedcentral.com/1471-2458/6/217
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review and patient consent were not required. Informa-
tion collected included baseline socio-demographic, clin-
ical, and provider characteristics; treatment information,
including initial regimens, the number of doses of anti-TB
medications, documentation of bacterial conversion of
sputum cultures from positive to negative, and case man-
agement characteristics such as therapy administration
and assessment of risk factors for treatment non-adher-
ence. For patients whose care was managed or co-man-
aged by the health department (approximately two-thirds
of the sample), the public health medical record was
essentially the same as the patient record. For patients
whose TB treatment was managed by private practitioners,
the public health medical record (hereinafter referred to
as the medical record) was frequently less complete, but
typically contained information sufficient for health
department oversight and reporting, including socio-
demographic, clinical, and treatment information, and
documentation of medical oversight and case manage-
ment activities provided by the health department. Since
local health departments use the medical record as the pri-
mary information source to complete the RVCT, and all
reported information should be contained in this record,
we considered it the "gold standard." Study staff did not
abstract information from the RVCT if a paper RVCT form
was included in the medical record, but all other data per-
taining to RVCT variables of interest were abstracted from
the medical record.
We used the California-specific RVCT reporting instruc-
tions in effect during the study period to determine how
information contained in the medical record should have
been reported [10]. These instructions, based largely on
CDC reporting instructions, contain additional detail for
a small number of variables. With minor exceptions, these
reporting instructions have remained in effect from the
study period until the present.
We assessed the validity of reported data for 53 RVCT var-
iables, consisting of 44 categorical variables and nine
dates. Table 1 presents a breakdown of the types of varia-
bles, values, and validation measures estimated. We fol-
lowed the CDC's recommendations for assessing data
quality in public health surveillance systems [11]. Specifi-
cally, we estimated the sensitivity and the predictive value
of the positive (PVP) reported value for each categorical
variable. We defined sensitivity as the probability of a pos-
itive value on the RVCT given documentation of a positive
value in the medical record. We defined the PVP as the
probability of a documented positive value in the medical
record given a positive value on the RVCT. We also esti-
mated the concordance, as a general measurement of
agreement, between data in the medical record and the
RVCT. We excluded from the validation analyses all null
values and values of 'unknown' and 'not done' on the
RVCT and 'not charted' in the medical record.
In order to maximize the comparability of the RVCT and
medical record for sputum smear and sputum culture
results, we restricted the validation of these variables to
results from patients diagnosed with pulmonary TB dis-
ease only who did not have positive results associated
with smear and/or culture non-sputum specimens. This
restriction was necessary because the field study did not
distinguish between results from sputum specimens,
other types of pulmonary specimens such as bronchial
wash or tracheal aspirate, and specimens from non-pul-
monary sites, whereas the RVCT distinguishes between
sputum and non-sputum specimen results. We also cre-
ated a variable for site of TB disease based on the sites of
smear and culture specimens documented in the medical
record and compared this to a variable calculated from
reported information regarding TB disease site.
We calculated two validation measures for dates: the abso-
lute mean difference in days (seven dates) or months (two
dates) between the RVCT and the medical record.
To assess the completeness of data from the case report
and the medical record, we estimated the proportion of
missing/unknown data in both data sources for all varia-
bles. For nine RVCT variables, values are expected depend-
ing on the value of another variable (e.g., a value for type
of chest x-ray abnormality or status of chest x-ray is
expected only if chest x-ray results are abnormal). For
these nine variables, we restricted our estimate of missing/
unknown values to instances in which a subsequent value
was expected, but missing, and did not count expected
absent values as 'missing'. We also excluded the value, 'not
done,' from the estimate of the proportion of missing/
unknown values for 15 RVCT variables associated with
test results.
We computed unbiased estimates for each validation
measure and the proportion of missing/unknown values
for each variable associated with the statewide cohort,
based on the original stratified random sampling design
(R survey sampling module version 2.8) [12,13]. For vali-
dation measures of non-date variables and missing/
unknown values from the RVCT and the medical record,
we also computed approximate 95% confidence intervals
for proportions, by transforming to a log-odds scale and
using the delta method [14]. For dates, we computed the
coefficient of variation (C.V.). Analyses were performed
using the SAS statistical software package (Release 9.1,
SAS Institute Inc., Cary, North Carolina) and R [15].BMC Public Health 2006, 6:217 http://www.biomedcentral.com/1471-2458/6/217
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Results and discussion
Most reported data submitted to the California TB Regis-
try on the RVCT were highly concordant with data
abstracted from the public health medical record. Survey-
weighted mean validation measures for 44 categorical var-
iables examined are presented in Table 2. Henceforth, all
results are presented as survey-weighted mean estimates
for the statewide cohort from which the sample was
drawn. Across all categorical variables, concordance
ranged from 46.8–100.0%; sensitivity from 26.4–100.0%;
and PVP from 1.1–100.0%. Concordance ranged from
84.4–99.0% for demographic data, 91.8–99.1% for
social/behavioral risk factor data, 46.8–100.0% for diag-
nostic and clinical data, and 48.6–100.0% for treatment
and case management data. At least 90% of the reported
values for 35 (79.5%) categorical variables were identical
with values in the medical record. Reported data for the
remaining nine (20.5%) categorical variables had lower
concordance with the medical record: status of abnormal
chest x-ray (46.8%); directly observed therapy (48.6%);
smear result for tissue or body fluid other than sputum
(49.2%); type(s) of tissue or body fluid for smears and
cultures other than sputum (76.4% and 73.9% respec-
tively); provider type (73.4%); occupation (84.4%); spu-
tum culture conversion (85.4%); and sputum smear result
(89.6%).
Results for the validity of dates are shown in Table 3. The
weighted mean absolute difference in dates in a month-
day-year format ranged from 2.6–110.9 days. For dates in
a month-year format, the weighted mean absolute differ-
ence ranged from 0.7–11.5 months.
The proportion of missing/unknown data for categorical
variables and dates for both the RVCT and the medical
record is presented in Table 4. Across all variables, the pro-
portion of missing/unknown data on the RVCT ranged
from 0.0% to 68.9%, and, for the medical record, the pro-
portion of missing/unknown data ranged from 0.0% to
78.9%. Certain RVCT variables associated with clinical
Table 1: Summary of variables and validation measures estimated in the medical record and case report
Variable Type
(n, %)
Variable Number* Medical Record Values Report of Verified Case 
of Tuberculosis (RVCT) 
Values
Number of Values and 
Validation Measures 
Estimated
n = 34 (77%) 1, 3, 4, 7, 8, 9,
10, 11, 12, 13,
15, 16, 17, 19,
21, 22, 24, 25,
26, 27, 28, 29,
30, 31, 32, 33,
34, 35, 39, 40,
41, 42, 43, 44
'Yes'
'No'
'Not Charted'
'Yes'
'No'
'Not Done'
(n = 15)
'Unknown'
2 × 2 tables:
Concordance
Sensitivity
Positive Predictive Value
Categorical
n = 44
2, 6, 14, 23,
36, 37, 38
Various values Various values n × n tables
(values = 3–6):
Concordance
n = 10 (23%) 2 × 2 tables: collapsed n × n tables 
to n (2 × 2) tables†
Sensitivity
Positive Predictive Value
5, 18, 20 n × n tables (values=96–268):
Concordance
Dates
n = 9
n = 7 (78%) Month/Day/Year
46, 48, 49, 50,
51, 52, 53
MM/DD/YYYY MM/DD/YYYY Absolute mean difference (days)
n = 2 (22%) Month/Year
45, 47
MM/DD/YYYY MM/YYYY Absolute mean difference 
(months)
* See Table 2, first column, for variable number (Note: these numbers do not correspond to the variable numbers on the RVCT form).
† For each of the n values, we constructed a 2 × 2 table from (1) the number of individuals for which the medical record and RVCT both exhibited 
that value, (2) the number for which only the medical record exhibited that value, (3) the number for which only the RVCT exhibited that value, and 
(4) the number for which neither exhibited that value. Specifically, for each k (k = 1, ..., n), we constructed a collapsed 2 × 2 table of values
 (i = 1, 2; j = 1, 2) according to   for each k = 1, ..., n. with alm being the 
values in the original n × n table (l = 1, ..., n, m = 1, ...n). (Here, δab is the Kronecker delta, i.e., δab = 1 if a = b and 0 otherwise.)
xij
k ()
xa ij
k
m
m
n n
il k ik jm k j
()=+ − () − () ⎡ ⎣ ⎤ ⎦ + − (
= =
∑ ∑ A
A
A
1 1
1 1 1 1 11 1 δδ δδ δδ δ ) ) − () ⎡ ⎣ ⎤ ⎦ 1 δmkBMC Public Health 2006, 6:217 http://www.biomedcentral.com/1471-2458/6/217
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Table 2: Weighted mean validation measures for categorical variables in Report of Verified Case of Tuberculosis (RVCT)
#* RVCT Variable Concordance
(95% CI†) %
Sensitivity of Reported 
Value (95% CI) %
Predictive Value of 
Reported Positive Value 
(95% CI) %
DEMOGRAPHIC
1 Sex 98.1 (96.7, 99.0) 99.7 (98.0, 99.9) 97.5 (95.3, 98.6)
2 Race 97.7 (96.3, 98.6) ND‡ ND ND ND
White ND ND 99.2 (97.5, 99.7) 97.0 (94.4, 98.4)
Black ND ND 95.3 (87.1, 98.4) 97.9 (88.8, 99.7)
Asian-Pacific Islander ND ND 97.5 (94.9, 98.8) 98.4 (96.3, 99.3)
American Indian/Alaska Native ND ND 50.0 (12.8, 87.2) 100.0 -§
3 Ethnicity 98.5 (97.2, 99.1) 97.6 (94.7, 98.9) 98.1 (95.5, 99.2)
Country of origin
4 U.S.-born 98.9 (97.7, 99.4) 99.1 (95.1, 99.9) 96.6 (92.8, 98.4)
5 Other country of origin 96.0 (93.6, 97.5) ND ND ND ND
6 Occupation 84.4 (80.7, 87.5) ND ND ND ND
Health care worker ND ND 78.2 (46.4, 93.7) 70.5 (41.3, 89.0)
Migratory agricultural worker ND ND 51.8 (25.1, 77.5) 81.1 (38.3, 96.7)
Other occupation ND ND 76.4 (69.8, 81.9) 89.0 (83.3, 92.9)
Not employed within past 24 months ND ND 93.5 (89.5, 96.0) 82.2 (76.9, 86.5)
7 Resident of long-term care facility at diagnosis 98.3 (97.1, 99.0) 67.8 (47.1, 83.3) 76.8 (57.8, 88.9)
8 Resident of correctional facility at diagnosis 99.0 (97.7, 99.6) 69.7 (45.7, 86.3) 100.0 -
SOCIAL AND BEHAVIORAL RISK FACTORS
9 Homeless within past 1–2 years|| 99.1 (96.9, 99.7) 97.3 (92.6, 99.0) 95.1 (75.9, 99.2)
10 Injecting drug user within past year 98.1 (96.5, 99.0) 63.5 (41.5, 81.0) 86.5 (59.8, 96.5)
11 Non-injecting drug user within past year 96.6 (94.6, 97.9) 70.1 (55.2, 81.7) 90.9 (74.6, 97.1)
12 Excess alcohol use within past year 91.8 (88.8, 94.0) 69.9 (61.0, 77.6) 96.8 (89.3, 99.1)
DIAGNOSTIC AND CLINICAL
13 Previous TB 94.6 (92.3, 96.2) 57.6 (45.0, 69.3) 93.5 (81.9, 97.9)
14 Site of disease 92.5 (90.4, 94.2) ND ND ND ND
Pulmonary only ND ND 96.7 (94.6, 97.9) 96.2 (94.3, 97.4)
Extra-pulmonary only ND ND 98.6 (96.8, 99.4) 81.6 (74.4, 87.0)
Both pulmonary and extra-pulmonary ND ND 51.1 (39.7, 62.4) 86.9 (73.9, 94.0)
15 Sputum smear 89.6 (86.0, 92.3) 90.5 (85.8, 93.7) 92.2 (87.9, 95.1)
16 Sputum culture 96.8 (94.2, 98.2) 100.0 - 96.8 (94.2, 98.2)
17 Smear of tissue/body fluids (non-sputum) 49.2 (38.4, 60.0) 31.2 (21.0, 43.6) 98.7 (98.1, 99.2)
18 Tissue/body fluid type (non-sputum) 76.4 (59.3, 87.8) ND ND ND ND
19 Culture of tissue/body fluid (non-sputum) 98.2 (94.6, 99.4) 100.0 - 98.2 (94.6, 99.4)
20 Tissue/body fluid type (non-sputum) 73.9 (66.0, 80.6) ND ND ND ND
Chest x-ray
21 Abnormal/normal 96.0 (94.0, 97.3) 99.1 (97.6, 99.7) 96.8 (94.8, 98.0)
22 If abnormal: cavitary/non-cavitary** 90.9 (88.0, 93.2) 75.1 (66.3, 82.3) 86.2 (78.0, 91.7)
23 If abnormal: stable/worsening/improving 46.8 (37.0, 56.9) ND ND ND ND
Stable ND ND 49.9 (36.0, 63.7) 53.7 (39.0, 67.9)
Worsening ND ND 52.0 (38.0, 65.7) 51.7 (37.8, 65.4)
Improving ND ND 26.9 (8.7, 58.6) 19.8 (6.5, 46.8)
24 Initial drug susceptibility testing done 100.0 - 100.0 - 100.0 -
Results of initial drug susceptibility testing††
25 Isoniazid 99.2 (98.1, 99.7) 92.5 (82.6, 97.0) 100.0 -
26 Rifampin 100.0 - 100.0 - 100.0 -
27 Pyrazinamide 92.1 (89.3, 94.2) 88.1 (68.8, 96.1) 100.0 -
28 Ethambutol 100.0 - 100.0 - 100.0 -
29 Streptomycin 98.3 (96.8, 99.1) 93.2 (78.8, 98.0) 92.0 (78.7, 97.3)
TREATMENT AND CASE MANAGEMENT
Initial treatment regimen
30 Isoniazid 98.2 (96.8, 99.0) 99.6 (98.8, 99.9) 98.6 (97.2, 99.3)
31 Rifampin 98.7 (97.5, 99.4) 99.9 (99.7, 100.0) 98.8 (97.6, 99.4)
32 Pyrazinamide 96.7 (95.1, 97.8) 98.1 (96.7, 98.9) 98.4 (97.1, 99.1)
33 Ethambutol 95.9 (94.0, 97.2) 98.8 (97.4, 99.4) 96.5 (94.6, 97.8)
34 Streptomycin 98.7 (97.7, 99.3) 40.3 (16.3, 70.1) 38.1 (14.1, 69.9)
35 Sputum culture conversion documented 85.4 (81.1, 88.8) 93.3 (89.5, 95.7) 87.8 (83.0, 91.3)
36 Reason therapy stopped‡‡ 97.9 (96.4, 98.8) ND ND ND NDBMC Public Health 2006, 6:217 http://www.biomedcentral.com/1471-2458/6/217
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tests have a value of 'not done.' Since the field study did
not distinguish between 'not done' and 'not charted' for
these variables and recorded both as 'not charted,' a
higher proportion of missing/unknown values was noted
in the medical record for variables such as results of
microscopic smear and culture of other tissue and body
fluids.
This is the first study in the U.S. to assess data validity and
completeness for the majority of the variables on the
RVCT. As the largest single reporter of U.S. TB surveillance
data, reporting over 4,000 cases during the 12-month
study period, our findings may have direct implications
for data quality of the U.S. TB surveillance system. These
findings may also be relevant to TB control programs in
other U.S. reporting areas or regions of the world. Areas
with established TB surveillance systems may benefit from
specific findings and evaluation methodology presented
[16], while regions with nascent surveillance systems may
apply general findings toward the successful development
and implementation of surveillance systems.
Our study found generally excellent data validity and
completeness for the RVCT variables assessed. From the
vantage point of disease control, the most important var-
iables, including initial drug regimen, initial drug suscep-
tibility test results, and patient outcome, were found to be
valid. These findings indicate a robust surveillance system
that completely and accurately captures essential informa-
tion to support TB control activities. The nine RVCT vari-
ables noted for which data was less concordant with the
medical record included demographic, clinical, and case
management variables. Data quality for some of these var-
iables may impair program planning and evaluation
efforts, especially in the areas of treatment adherence and
treatment response, policy development, research, pro-
gram advocacy, and the allocation of resources for TB con-
trol efforts. Variables with potentially the greatest impact
on these activities are discussed below in the order of
importance.
Ensuring patient adherence to treatment is a core function
of TB control programs. Non-adherent patients may be
involved in on-going disease transmission and are at
increased risk of treatment failure and developing drug-
resistant disease [5,17-19]. Directly observed therapy
administration (DOT), in which health department per-
sonnel watch the patient swallow each dose of medica-
tion, is recommended by WHO and CDC to ensure
adherence through the required six to nine months of TB
treatment (and longer for treatment of multi-drug resist-
ant disease)[1,2,4,20]. Since completion of TB therapy is
based on receipt of a prescribed number of doses of a ther-
apeutic regimen, DOT also ensures that patients receive
the correct number of doses to complete therapy and
achieve cure.
Completion of therapy ND ND 97.8 (96.0, 98.8) 100.0 -
Lost/uncooperative or refused therapy ND ND 98.4 (98.4, 98.4) 62.9 (46.1, 77.1)
Died ND ND 99.2 (96.6, 99.8) 93.3 (84.2, 97.4)
37 Provider type 73.4 (69.8, 76.7) ND ND ND ND
Health Department only (HD) ND ND 74.7 (69.7, 79.1) 90.3 (86.7, 93.0)
Private/Other only ND ND 79.6 (74.6, 83.9) 80.0 (74.2, 84.8)
Both HD and Private/Other ND ND 38.6 (26.4, 52.5) 18.1 (12.0, 26.4)
38 Therapy administration 48.6 (44.4, 52.8) ND ND ND ND
Directly Observed Therapy (DOT) only ND ND 29.7 (10.5, 60.4) 1.1 (0.4, 2.9)
Self-administered Therapy (SAT) only ND ND 72.0 (66.7, 76.7) 88.3 (83.1, 92.0)
Both DOT and SAT ND ND 26.4 (21.3, 32.2) 82.7 (73.1, 89.4)
39 Final drug susceptibility testing done ‡‡ 100.0 - 100.0 - 100.0 -
Results of final drug susceptibility testing††§§
40 Isoniazid 100.0 - 100.0 - 100.0 -
41 Rifampin 98.4 (97.3, 99.0) 92.6 (79.7, 97.5) 100.0 -
42 Pyrazinamide 90.5 (59.5, 98.4) - - - -
43 Ethambutol 90.3 (59.0, 98.4) - - - -
44 Streptomycin 100.0 - 100.0 - 100.0 -
Note: All results are presented as survey-weighted mean estimates for the statewide cohort from which the sample was drawn.
* Variable number (see Table 1)
† Confidence interval
‡ Not determined, by design
§ No value computed (e.g., division by 0)
|| RVCT defines homeless within 1 year of diagnosis; medical record review defined homeless within 2 years of diagnosis
** RVCT values: cavitary, non-cavitary consistent with TB, non-cavitary not consistent with TB; medical record review values: cavitary, abnormal/
non-cavitary
†† As a result of a very small number of second-line drug susceptibility test results, these results are not presented.
‡‡ Excludes 9 cases: 1 case without TB; 5 cases reported as 'moved' on RVCT; 3 cases reported as 'other" on RVCT
§§ Based on small number of cases with final susceptibility testing performed; therefore estimates are subject to considerable instability
Table 2: Weighted mean validation measures for categorical variables in Report of Verified Case of Tuberculosis (RVCT) (Continued)BMC Public Health 2006, 6:217 http://www.biomedcentral.com/1471-2458/6/217
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To support the core function of DOT, TB control programs
must have valid data with which to evaluate the effective-
ness of their DOT activities. RVCT instructions define
'DOT only' as 100% of doses by DOT; 'self-administered
therapy only (SAT)' as 0 doses by DOT; and 'both DOT
and SAT' as ≥1 DOT dose and ≥1 SAT dose. However, local
health departments generally do not implement these
strict definitions, which would require them to report
therapy given predominantly by DOT or predominantly
by SAT as 'both DOT and SAT,' thereby significantly limit-
ing the usefulness of this value. The approach to reporting
this variable varies widely by jurisdiction and within juris-
dictions (JES personal experience). Concordance between
data on the RVCT and the medical record for 'DOT only'
was 48.6%. However, the PVP for reported 'DOT only' was
1.1%, indicating that DOT, as defined in the reporting
instructions, is rarely provided when it is reported. The
PVP for reported 'SAT only,' by comparison, was 88.3%,
indicating that 'SAT only' is employed when reported for
the vast majority of cases. Thus 'SAT only' may be a more
valid indicator of therapy administration. For this reason,
many local TB control programs and the state health
department in California use 'inappropriate SAT' to eval-
uate their DOT programs.
The CDC workgroup proposed substantial revisions for
this variable, increasing the current three categories to
five. Under these proposed revisions, 'total DOT' is
defined as 90–100% of doses by DOT, 'predominantly
DOT' as 80–89% DOT, and 'predominantly SAT' is
defined as 1–49% doses by DOT. The five proposed values
correspond to the impact that varying proportions of
treatment given by DOT are likely to have on adherence
and much better conform to the realities of therapy
administration in local health departments. Under this
proposed revision, the reported PVP for therapy provided
at least predominantly by DOT would improve from 1.1%
to 49.9% (not shown). The proposed revised definition of
therapy administration is likely to result in substantially
more valid and meaningful data for this variable. How-
ever, even with these revisions, the challenges local pro-
grams face in accurately counting doses received by DOT
over a patient's entire treatment may continue to result in
inaccurate reporting of the proportion of DOT doses after
revised definitions are implemented.
Although CDC recommends universal DOT for TB ther-
apy [4], many California TB control programs do not have
sufficient resources to provide universal DOT. In this cir-
cumstance, it is recommended that programs prioritize
patients for DOT by factors associated with an increased
risk of treatment non-adherence and/or the consequences
of non-adherence [20]. Drug and alcohol abuse and
homelessness figure largely in these factors. Although
concordance between data on the RVCT and in the medi-
cal record for drug and alcohol abuse ranged from 91.8–
98.1%, sensitivity for reported data ranged from 63.5–
70.1%. The latter finding indicates that the medical record
documented the presence of one or more of these factors
approximately one-third more often than was reported on
the RVCT.
This review highlighted another issue related to the
reporting of these social/behavioral risk factor variables. A
relatively high proportion (ranging from 22.1–63.8% for
these four variables) of medical records contained no
information regarding alcohol use, injection and non-
injection drug use, and homelessness (not shown). For
Table 3: Weighted absolute mean difference between dates on the case report and the medical record
Dates Weighted Absolute Mean
Difference (days)
Coefficient of Variation (C.V.) %
Month/day/year dates
Birth date 48.4 39.9
Treatment start 2.6 17.0
Isolate collection for drug susceptibility testing 13.0 26.1
First positive culture 6.1 31.0
First consistently negative culture 25.0 15.1
Treatment stop 19.2 11.3
Isolate collection for final susceptibility testing 110.9* 44.5
Dates Weighted Absolute Mean Difference 
(months)
Coefficient of Variation (C.V.) %
Month/year dates
Case reported to local health department 0.74 10.0
Entry into U.S. 11.5 20.2
Note: All results are presented as survey-weighted mean estimates for the statewide cohort from which the sample was drawn.
* Based on small number of cases with final susceptibility testing performed; therefore estimate is subject to considerable instabilityBMC Public Health 2006, 6:217 http://www.biomedcentral.com/1471-2458/6/217
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Table 4: Weighted mean estimates for the proportion of missing/unknown values on case report and medical record
#* Report of Verified Case of Tuberculosis (RVCT) Variable RVCT Missing/
Unknown %
(95% CI)†
Public Health 
Medical Record 
Missing/Unknown % 
(95% CI)
DEMOGRAPHIC
1S e x 0.0 -‡ 0.0 -
2R a c e 0.0 - 1.3 (0.7, 2.6)
3 Ethnicity 0.0 - 1.4 (0.7, 2.6)
Country of origin
4 U.S.-born 0.6 (0.2, 1.5) 2.7 (1.7, 4.2)
5 Other country of origin 0.0 - 0.1 (0.1, 0.1)
6 Occupation 8.2 (6.3, 10.6) 23.6 (20.4, 27.1)
7 Resident of long-term care facility at diagnosis 0.2 (0.1, 0.4) 7.6 (5.8, 9.9)
8 Resident of correctional facility at diagnosis 0.1 (0.0, 0.3) 6.7 (5.1, 8.9)
SOCIAL/BEHAVIORAL RISK FACTORS
9 Homeless within past 1–2 years§ 1.9 (1.1, 3.2) 63.8 (59.9, 67.5)
10 Injecting drug user within past year 8.0 (6.2, 10.2) 22.1 (19.1, 25.4)
11 Non-injecting drug user within past year 7.8 (6.0, 10.0) 23.4 (20.3, 26.8)
12 Excess alcohol use within past year 7.6 (5.9, 9.8) 24.1 (21.0, 27.6)
DIAGNOSTIC AND CLINICAL
13 Previous TB 0.0 - 19.7 (16.8, 22.9)
14 Site of disease 0.0 - 0.0 -
15 Sputum smear|| 4.9 (3.4, 7.2) 6.0 (4.2, 8.7)
16 Sputum culture|| 15.1 (12.1, 18.7) 14.4 (11.5, 17.8)
17 Smear of tissue/body fluids (non-sputum)|| 0.6 (0.3, 1.5) 78.9 (75.6, 82.0)
18 Tissue/body fluid type (non-sputum)* * 0.0 - 0.0 -
19 Culture of tissue/other body fluid (non-sputum)|| 0.3 (0.1, 1.1) 63.6 (59.8, 67.2)
20 Tissue/body fluid type (non-sputum) * * 0.0 - 0.0 -
Chest x-ray results
21 Abnormal/normal|| 0.6 (0.3, 1.5) 8.7 (6.8, 11.2)
22 If abnormal: cavitary/non-cavitary** 0.1 (0.0, 0.4) 0.0 -
23 If abnormal: stable/worsening/improving** 68.9 (64.8, 72.7) 45.3 (40.9, 49.7)
24 Initial susceptibility testing done 0.0 - 1.7 (0.9, 3.1)
Results of initial susceptibility testing, if done††
25 Isoniazid|| 0.0 - 3.1 (2.0, 4.9)
26 Rifampin|| 0.7 (0.3, 1.8) 21.2 (18.1, 24.5)
27 Pyrazinamide|| 0.0 - 3.1 (2.0, 4.9)
28 Ethambutol|| 0.0 - 4.1 (2.8, 6.0)
29 Streptomycin|| 0.0 - 2.9 (1.8, 4.6)
TREATMENT AND CASE MANAGEMENT
Initial treatment regimen
30 Isoniazid 0.0 - 0.0 -
31 Rifampin 0.0 - 0.0 -
32 Pyrazinamide 0.1 (0.0, 0.3) 0.0 -
33 Ethambutol 0.0 - 0.0 -
34 Streptomycin 0.1 (0.0, 0.3) 0.0 -
35 Sputum culture conversion, if ever sputum culture positive** 1.6 (0.7, 3.5) 0.0 -
36 Reason therapy stopped 0.7 (0.3, 1.5) 0.0 -
37 Provider type 0.2 (0.0, 1.3) 0.0 -
38 Therapy administration 3.5 (2.4, 5.2) 0.0 -
39 Final susceptibility testing done‡‡ 0.0 -
Results of final susceptibility testing, if done‡‡
40 Isoniazid||‡‡ 0.0 - 5.7 (1.5, 19.6)
41 Rifampin||‡‡ 0.0 - 5.7 (1.5, 19.6)
42 Pyrazinamide||‡‡ 5.1 (0.9, 25.2) 11.9 (4.9, 26.2)
43 Ethambutol||†† 0.0 - 6.4 (1.9, 19.3)
44 Streptomycin||‡‡ 0.0 - 9.8 (3.3, 25.4)
DATES
45 TB case report date 0.0 - 5.7 (4.1, 7.8)
46 Date of birth 0.0 - 0.1 (0.0, 0.3)
47 Date arrived in United States (foreign-born cases)** 9.2 (7.0, 12.1) 15.1 (12.1, 18.6)BMC Public Health 2006, 6:217 http://www.biomedcentral.com/1471-2458/6/217
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medical records that lacked information on these varia-
bles, a large proportion of RVCTs did not report
'unknown.' The vast majority of these RVCTs reported that
these four factors were explicitly absent (ranging from
76.9–94.7%), rather than present (ranging from 1.3–
3.4%) (not shown). Local TB control staff may have pro-
cured information regarding these factors outside the
medical record and used a paper RVCT only to document
this information prior to reporting it. In this circumstance,
since data from paper RVCTs in the medical record were
not abstracted by the study team, more complete informa-
tion for these variables may be contained on the RVCT
than the abstracted medical record. However, it is unlikely
that such a high proportion of these variables, in compar-
ison to other variables, were differentially reported only
on a paper RVCT, without other documentation in the
medical record. It is also possible that the absence of doc-
umentation regarding these factors in the medical record
was taken as evidence of their absence by local reporting
staff and others. During data abstraction, approximately
one-sixth of the medical records that had missing infor-
mation for drug and alcohol abuse and homelessness
were documented as 'no,' rather than 'not charted.' Thus,
an even greater proportion of medical records did not
contain information on these important factors associated
with treatment non-adherence.
Accurate and complete elicitation and reporting of sub-
stance abuse and homelessness should be a high priority
to ensure that patients with these factors are identified
and prioritized for DOT and other adherence-promoting
strategies. These core risk factors should be part of stand-
ard intake forms for suspected TB patients. In addition to
DOT, homeless patients and those with substance abuse
often require more complex case management [5,17]. For
this reason, CDC's revised funding formula, implemented
in January 2005 (K. Castro, Director, CDC Division of
Tuberculosis Elimination, letter to colleagues; October 15,
2004), increased funding for cases with these and other
characteristics. Programs receive less federal funding than
warranted if information about homelessness and sub-
stance abuse within the year prior to diagnosis is not accu-
rately elicited from patients and reported.
Another factor that may be associated with non-adher-
ence to treatment is a prior episode of TB disease, which
also increases the risk of drug-resistant TB disease [5,17-
19]. Thus, it is a high priority to identify patients with pre-
vious TB to ensure that they receive DOT and an appropri-
ate initial drug regimen. Information about a prior
episode of TB is also important to distinguish between pri-
mary and acquired drug-resistant TB, which should lead
to very different TB control strategies. Although 94.6% of
RVCT data for previous TB was concordant with the med-
ical record, sensitivity for reported previous TB was
57.6%, indicating that previous TB was documented in
the medical record over 40% more often than it was
reported on the RVCT. Furthermore, it is of note that
almost one-fifth of medical records lacked any informa-
tion regarding previous TB. However, unlike other cate-
gorical variables on the RVCT, the paper RVCT restricted
values for previous TB to 'yes' and 'no,' while the elec-
tronic form permitted the entry of 'unknown.' If local
health departments use the paper RVCT or similar forms,
based on the RVCT, to capture information from the med-
ical record for computer data entry, none of the cases with
missing information for previous TB in the medical record
could be correctly reported as 'unknown.' In the reporting
of previous TB that was not documented in the medical
record, an estimated 2.2% (11) of the statewide cohort
was reported with previous TB versus 97.8% (509)
reported without previous TB (not shown). This may
result in an underestimate of cases with previous TB. From
the standpoint of data quality, the electronic information
48 Treatment start date 0.0 - 0.0 -
49 Date specimen collected for initial drug susceptibility testing** 0.0 - 2.1 (1.2, 3.7)
50 Date specimen collected on initially positive sputum culture** 0.0 - 0.0 -
51 Date specimen collected on first consistently negative sputum culture** 1.4 (0.5, 3.8) 0.2 (0.2, 0.2)
52 Date TB treatment stopped 0.2 (0.2, 0.2) 0.0 -
53 Date specimen collected for final drug susceptibility testing††‡‡ 5.1 (0.9, 25.2) 9.8 (3.3, 25.4)
Note: All results are presented as survey-weighted mean estimates for the statewide cohort from which the sample was drawn.
* Variable number (see Table 1)
† Confidence Interval
‡ With an estimate of 0.0% missing/unknown, a confidence interval was not determined
§ RVCT defines homeless within 1 year of diagnosis; medical record review defined homeless within 2 years of diagnosis
|| 'Not done' on RVCT excluded
** For nine RVCT variables, values are expected depending on the value of another variable (e.g., a value for type of chest x-ray abnormality or 
status of chest x-ray is expected only if chest x-ray results are abnormal). For these nine variables, we restricted our estimate of missing/unknown 
values to instances in which a subsequent value was expected, but missing, and did not count expected absent values as 'missing'.
†† As a result of a very small number of second-line drug susceptibility test results, these results are not presented, either for initial or final drug 
susceptibility testing.
‡‡ Based on small number of cases with final susceptibility testing performed; therefore estimate is subject to considerable instability
Table 4: Weighted mean estimates for the proportion of missing/unknown values on case report and medical record (Continued)BMC Public Health 2006, 6:217 http://www.biomedcentral.com/1471-2458/6/217
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system should capture the same values as the paper form
for each RVCT variable, and variables should be structured
to permit reporting of 'unknown' values.
The time to documented sputum culture conversion (con-
version of an initially positive M. tuberculosis sputum cul-
ture to a consistently negative result) is an important
indicator of a patient's response to therapy. As such,
timely sputum culture conversion is an important evalua-
tion measure for TB control programs. If delayed sputum
culture conversion (conversion >60 days) is noted, the
following interventions are recommended: assessment of
factors potentially associated with suboptimal response to
treatment, extended duration of TB therapy, and initiation
of DOT (if not already provided) [20]. Reported data for
documentation of sputum culture conversion were 85.4%
concordant with data in the medical record, and the PVP
for a reported positive was 87.8%, indicating that greater
than 10% of cases reported with sputum culture conver-
sion lacked documentation in the medical record. For
cases with documented sputum culture conversion, the
absolute mean difference between the RVCT and medical
record in the date for the first consistently negative spu-
tum culture was 25.0 days. The magnitude of this differ-
ence is almost half of the timeframe (60 days)
recommended to trigger interventions for delayed sputum
culture conversion noted above. Complete and accurate
data validity for these variables is essential for TB control
programs to evaluate their performance in achieving
timely sputum culture conversion. This performance
measure highlights medical oversight, case management,
and laboratory functions. Inadequate data impairs the
ability of programs to identify and address problems in
these important areas, to prevent on-going transmission
from patients who remain sputum culture positive, and to
ensure cure of TB patients.
RVCT data for cases with an initial abnormal chest x-ray
were only 46.8% concordant with the medical record in
assessing chest x-ray status (stable, improving, or worsen-
ing) of a follow-up chest film. The poor concordance has
multiple possible explanations: unclear RVCT instructions
regarding the timeframe from the initial to the follow-up
chest x-ray; follow-up chest x-ray results received after the
RVCT was submitted; multiple chest x-ray results with
potentially differing values; and inadequate correspond-
ence between RVCT values and terms used in chest x-ray
reports. The variable, 'chest x-ray status,' is used primarily
to execute an algorithm to verify that patients without
positive M. tuberculosis cultures have TB disease [21]; since
only culture positive cases were included in the study sam-
ple, validity of this variable is not relevant for cases in the
study population. But poor concordance between RVCT
data and the medical record suggests that using a reported
change in chest x-ray status as a criterion to verify culture-
negative TB cases may be problematic. A high proportion
of data for this variable was also missing/unknown from
both the medical record and the RVCT (45.3% and
68.9%, respectively). The CDC workgroup proposed to
eliminate this variable entirely from the RVCT; poor data
validity and a high proportion of missing data in our
study support this proposal.
As noted, data for the smear result of tissue or body fluid
other than sputum were 49.2% concordant. On both the
RVCT and the medical record, at least one tissue or body
fluid type was associated with each positive smear result,
with 76.4% concordance on tissue/body fluid types(s).
Among discordant results for positive smear, 54.4% were
associated with a specific tissue/body fluid type that was
documented in the medical record, but not reported on
the RVCT (not shown). Conversely, the RVCT reported
45.6% of positive smear results associated with a specific
tissue or fluid that was not documented in the medical
record (not shown). Local TB control staff may have
received telephone reports of these results and docu-
mented them only on a paper RVCT in the medical record
before reporting it. In this circumstance, since the study
team did not abstract data from paper RVCTs in the med-
ical record, more complete information on these variables
for some cases may be contained on the RVCT than the
abstracted medical record. Results that were documented
in the medical record, but were not reported may be
explained by the retrospective nature of the field study
which benefited from results and documentation that
may not have been available at the time the RVCT was
submitted. Data on microscopic smear results for tissue or
body fluid other than sputum are used for TB case confir-
mation among a very small proportion (approximately
0.5%) of TB cases who lack sputum and/or other cultures
to confirm TB [21]. Since all cases in the sample were M.
tuberculosis culture positive, discordance of data between
the RVCT and the medical record for these variables has
little consequence for the study population. Among
patients whose TB case confirmation relies on micro-
scopic smear results, the absence of these data could delay
case confirmation and reporting. The proposed RVCT revi-
sion provides much more detailed and specific instruc-
tions for reporting and updating information for these
variables that will likely improve data quality.
Both local and state TB control programs often stratify
program performance measures by provider type to better
understand the role of public versus private provider in
the measurement of interest and to inform interventions.
Our study found that RVCT data for provider type was
73.4% concordant with the medical record. These find-
ings are likely the result of instructions and categories that
do not accurately reflect the range and complexity of pro-
vider types involved in the direct care of patients with anBMC Public Health 2006, 6:217 http://www.biomedcentral.com/1471-2458/6/217
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illness lasting 6–18 months. Proposed revisions of the
CDC workgroup would expand categories for provider
type, clarify definitions and instructions, and allow
reporting of as many provider types that apply.
RVCT data for case occupation in the year prior to TB diag-
nosis were 84.4% concordant with data in the medical
record. The sensitivity for migratory agricultural worker
was 51.8%, indicating that nearly twice as many of these
workers were documented in the medical record but not
reported on the RVCT. The sensitivity for 'other employ-
ment' (employment other than migratory agricultural
worker, health care worker, and correctional employee)
was 76.4%. The vast majority of patients who were identi-
fied with other employment in the medical record were
reported as 'unemployed' on the RVCT (not shown). The
CDC workgroup proposed to expand and redefine occu-
pational categories and clarify instructions for reporting
case occupation.
Turning from the categorical variables to the nine date var-
iables we compared, we found that for dates in month/
day/year format, the weighted mean absolute difference
in days between the medical record and the report was
generally within 25 days, except for birth date which had
a difference of 48 days. However, any difference may be
problematic when a variable, such as birth date, is used to
match cases in surveillance datasets. For foreign-born
cases, the weighted mean difference between the date of
entry to the U.S. (in month/year format) on the RVCT and
in the medical record was 11.2 months. Such discordance
may be related to recall bias of the TB patient and may be
difficult to rectify. Alternatively, it may be related to
unclear reporting instructions principally affecting
patients with repeated entries to the U.S. or with different
countries of birth from their countries of origin.
With notable exceptions, across all variables, the propor-
tion of missing data on the RVCT was lowest for demo-
graphic variables, drug susceptibility test results, and the
initial treatment regimen. Across all variables, the mean
proportion of missing/unknown data was greater in the
medical record (9.8%) versus the RVCT (2.9%), including
data noted above for drug and alcohol use, homelessness,
and previous TB. However, it should be noted that 15
RVCT variables pertaining to clinical tests have a 'not
done' value, which was abstracted as 'not charted' in the
field study. Missing data potentially compromise the
quality of surveillance data and the surveillance system,
especially if data are not missing completely at random. In
the latter circumstance, biases may be introduced that
impair our understanding of the true epidemiology of TB
and compromise activities that rely on accurate data.
The study findings provide strong support of the CDC
workgroup's proposed revisions to the 1993 RVCT,
including restructuring certain variables (e.g., previous TB,
DOT, type of health care provider); enhanced reporting
instructions for other variables (e.g., proposed instruc-
tions specify submission of updated information as it
becomes available for drug and alcohol abuse, and smear
and culture results of tissue and other body fluids); clari-
fication of instructions for some date fields (e.g., date of
entry to the U.S. for foreign-born cases); and deletion of
one variable (e.g., chest x-ray status).
Implementation of the proposed RVCT is likely to make a
substantial contribution to improving the validity and
value of TB surveillance data. However, additional inter-
ventions are needed to ensure valid TB surveillance data
nationally. As more and more health departments imple-
ment comprehensive electronic patient management sys-
tems, it is important for the accuracy of the RVCT
generated by these systems to be fully evaluated. These
systems should be designed to ensure that definitions and
values for RVCT variables are consistent nationally and
reinforced by the functionality of the system so that the
information needed to support and sustain our TB control
activities is accurately captured.
Although CDC has provided instructions for completing
the RVCT, detailed documentation regarding electronic
reporting, and extensive electronic data validation, it has
not provided guidance on effective data QC practices at
the local level. An informal survey of many California
health departments revealed that nearly half did not have
processes in place to check the completed RVCT against
the medical record, and 80% did not check for data entry
errors [22]. Since it is likely that gaps in QC practices exist
broadly across the nation and there are numerous gener-
ally applicable QC practices for an established TB surveil-
lance system, it is appropriate for the CDC to address
these deficiencies and implement enhanced QC practices
for the surveillance system. In order to ensure data quality
in surveillance systems, development of best practices for
recordkeeping and documentation in the public health
medical record is also needed. As public heath programs
and bioterrorism preparedness entities move toward elec-
tronic surveillance and patient management systems, the
importance of electronic data quality in effective patient
management cannot be overemphasized.
To improve and ensure RVCT data quality as CDC imple-
ments the revised RVCT, targeted interventions at the
national, state, and local levels are also needed. Potential
interventions include the following:
▪ National levelBMC Public Health 2006, 6:217 http://www.biomedcentral.com/1471-2458/6/217
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▪ Field test proposed RVCT revisions and reporting
instructions prior to their implementation
▪ Develop recommendations and tools for QC prac-
tices at the local level that facilitate implementation of
effective practices
▪ Develop best practices and tools for recordkeeping
and documentation to support accurate and complete
capture of data for RVCT variables
▪ Develop and maintain a TB surveillance users group
to provide on-going training and capacity-building of TB
registry staff nationally
▪ State level
▪ Provide regular training to local TB control staff who
complete and enter the RVCT to ensure that staff under-
stand definitions and instructions and appreciate the
importance of data quality
▪ Modernize and centralize user-assistance resources
(i.e., Help functions) either directly within new informa-
tion systems or via the World Wide Web to ensure access
and uniform distribution of revisions
▪ Provide technical assistance to support implementa-
tion of QC practices by local staff
▪ Local level
▪ Expand use of data QC procedures
▪ Implement effective recordkeeping and documenta-
tion in the public health medical record to support com-
plete and accurate capture of data for RVCT variables
▪ Routinely update case reports as more current case
information becomes available
▪ Ensure that replacement or upgraded information
systems can capture TB surveillance data according to
national requirements
There are several limitations to this study. First, the study
population is drawn from cases counted during 6/1/96-5/
31/97. However, significant statewide interventions to
improve data quality have not been undertaken since
1997, nor have the noted structural problems with RVCT
variables or unclear reporting instructions been resolved.
For these reasons, it is likely that findings of the study sub-
stantially reflect data quality at the present time. Second,
the findings may not be representative of RVCT data valid-
ity in other states or in other health jurisdictions in Cali-
fornia. Third, the field study was not primarily designed to
validate the RVCT; some definitions in the field study do
not exactly match RVCT definitions (e.g., history of home-
lessness), and a small number of RVCT variables were not
abstracted from the medical record so that they could not
be validated. Fourth, the medical record may be an imper-
fect "gold standard", and there may be situations in which
more accurate and complete information is reported than
is contained in the medical record. Fifth, abstractors
coded approximately one-sixth of medical records that
lacked documentation for homelessness and substance
abuse as explicitly lacking these factors. This may have
resulted in an underestimate of the relatively high propor-
tion of RVCTs that recorded the absence of these factors,
with no documentation in the medical record. Sixth, the
estimates for sputum smear and sputum culture were less
robust than for other variables because of the way that
data was abstracted in the field study. In assessing the
validity of these two variables, we limited the comparison
to patients with pulmonary TB only without non-sputum
specimen results.
In closing the discussion on limitations, several interpre-
tive comments regarding the validation measures are in
order. In general, concordance is most appropriate in
assessing the level of agreement between two equivalent
data sources, rather than a primary and secondary data
source. Moreover, because concordance does not account
for agreement that occurs by chance alone, our estimates
of concordance should be considered 'high' estimates for
measures of data validity. Similarly, estimates for sensitiv-
ity of the reported positive value should also be seen as
'high' estimates, since we restricted our calculations to
'yes' and 'no' values on the RVCT and medical record. In
fact, if the medical record contained documentation of a
positive value that was reported on the RVCT as
'unknown' or 'not done,' our estimates would have
excluded these discordant values, thereby resulting in a
higher estimate of sensitivity.
Conclusion
This evaluation provides unique information on the
validity of TB surveillance data in a large national public
health disease surveillance system. Since California has
contributed over 20% of U.S. TB cases annually over the
last decade, these findings may have implications for the
validity of TB surveillance data nationally. Collection of
valid TB surveillance data is critical to the public's health.
Invalid data may have unintended consequences, includ-
ing impaired understanding of the true epidemiology of
TB; compromised program planning, evaluation, and
research; inaccurate targeting of interventions; inadequate
TB prevention and control policies; and inappropriate
allocation of resources.BMC Public Health 2006, 6:217 http://www.biomedcentral.com/1471-2458/6/217
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Our study found that data validity and completeness for
most reported variables were excellent, indicating a robust
surveillance system. However, lower data validity was
noted for nine categorical (20.5%) variables, with the
most important impacts on evaluation of DOT, a core
component in TB control programs to ensure treatment
adherence and cure. In addition, it is likely that some of
the factors (e.g., homelessness, substance abuse, and pre-
vious TB) on which TB control programs prioritize
patients for DOT may not be captured accurately and
completely by the RVCT, further compromising DOT
activities and our evaluation of them.
The study findings provide compelling evidence in sup-
port of the CDC workgroup's proposed revisions of the TB
case report. The proposed enhanced instructions and def-
initions, revisions to variable structures, and the addition
of new variables are likely to contribute substantially both
to improved data quality and more useful data. Since the
RVCT remains under revision and will undergo stake-
holder review before it is finalized, additional revisions
are anticipated. Regardless, greater attention to QC and
recordkeeping at the national, state, and local levels will
help to ensure that implementation of the revised RVCT
achieves maximum impact.
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